Safety backlash tightens

Medical societies, state pharmacy boards, or early adverse-event reports push FDA to add stricter controls. The administration does not fully abandon broader peptide access, but the commercial opportunity becomes more compliance-heavy and less scalable.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.